
Assessing that the efficacy of a cancer therapeutic is an integral part of its path to regulatory approval, we review the history that led to our current assessment method, Response zzso zzso in Solid zzso zzso We describe the efforts of zzso and zzso to zzso response assessments in zzso zzso and how this was adapted in the World Health Organization zzso zzso Two decades later, zzso was advanced to streamline WHO and improve its zzso We describe the ways in which thresholds established by zzso and zzso to provide accuracy and zzso evolved to become measures of efficacy and why they have been zzso While we recognize zzso is far from zzso need of modification as a measure of efficacy for some agents and in some zzso the majority of solid tumors, it is very zzso We argue that over time, the efficacy thresholds established by WHO and then zzso have proved their worth, and we zzso 10 years of zzso Food and Drug Administration zzso approvals in solid tumors to support our position that current zzso thresholds should be zzso 

